Anthropic PBC has introduced Claude Science, a new software platform launching on June 30 that promises to fundamentally reshape how scientists conduct research by automating labour-intensive tasks across biology and chemistry disciplines. The tool represents the artificial intelligence firm's latest push to establish itself as an indispensable partner for professional sectors beyond consumer applications, as the San Francisco-based company positions itself for a potential initial public offering by autumn with a current valuation of US$965 billion (RM3.94 trillion).
The platform consolidates access to more than 60 scientific databases into a single interface, allowing researchers to formulate queries in plain language rather than navigating multiple information sources separately. By automating multistep workflows—including critical tasks such as predicting protein structures—Claude Science reduces the time scientists spend on routine computational work and enables them to concentrate on higher-level analysis and interpretation. The system will initially be offered as a beta release exclusively to Anthropic's paying subscribers, creating a tiered access model typical of the firm's broader commercialisation strategy.
Anthropovic's initiative arrives as the artificial intelligence industry confronts mounting pressure to demonstrate tangible real-world value beyond technological prowess. Chief executive officer Dario Amodei addressed this directly at the San Francisco launch event, emphasising that the company must now translate ambitious claims into measurable outcomes for patients and stakeholders. His remarks reflect a broader industry reckoning, particularly following the significant market disruption triggered by Anthropic's February introduction of Claude Cowork—a legal automation tool designed to handle contract reviews and legal briefings—which contributed to approximately US$1 trillion (RM4.08 trillion) in stock market losses as investors recalibrated expectations around professional services disruption.
The timing of Claude Science's unveiling carries particular significance given recent geopolitical tensions surrounding advanced AI technology. Merely two weeks prior to the announcement, Anthropic had restricted access to its most sophisticated models—Fable 5 and Mythos 5—in compliance with Trump administration directives aimed at preventing foreign nationals from obtaining frontier AI capabilities. Subsequently, on June 26, the company obtained regulatory approval to partially restore Mythos 5 access after resolving national security concerns, though restrictions on Fable 5 remain unchanged. This regulatory environment underscores the complex intersection of technological innovation, national security policy, and commercial advancement shaping the AI landscape.
Anthropovic's announcement also revealed an ambitious internal initiative to establish preclinical drug discovery programs developed entirely in-house. According to Eric Kauderer-Abrams, the company's head of life sciences, these programs will deliberately target therapeutic areas and disease indications that traditional pharmaceutical and biotech companies consider commercially unattractive—a strategic position that could unlock value in neglected rare diseases or conditions with limited market demand. This diversification into life sciences represents a significant expansion of Anthropic's business ambitions, moving beyond pure software provision into direct involvement in drug development pipelines.
The pharmaceutical industry's leadership has embraced this partnership with measured optimism tempered by realism about AI's current capabilities. Vas Narasimhan, chief executive officer of pharmaceutical giant Novartis AG and an Anthropic board member, appeared alongside Amodei to articulate the sector's perspective. Narasimhan acknowledged that while AI companies have made bold claims about transforming drug discovery, the proof lies in delivering genuine clinical benefits to patients rather than making theoretical assertions. His comments reflect the considerable pressure within pharmaceutical development to move beyond hype cycles toward demonstrable efficacy.
Navarsimhan also raised the critical issue of regulatory frameworks governing artificial intelligence deployment in healthcare and research contexts. He expressed concerns that crisis events might become the catalyst for implementing appropriate oversight mechanisms, suggesting that proactive regulation would be preferable to reactive policymaking. This position aligns with growing consensus among institutional leaders that the lack of coherent AI governance structures poses risks to both innovation sustainability and public trust. For Malaysian and Southeast Asian policymakers observing these dynamics, the comment carries particular relevance as regional governments develop their own AI governance approaches.
Claude Science leverages existing Claude models released by Anthropic, most notably the Opus 4.8 version unveiled in May. A crucial feature addressing scientific credibility concerns is the inclusion of traceable provenance information embedded within model outputs. This transparency mechanism allows researchers to verify the accuracy and sources of information generated by the system, addressing longstanding concerns about artificial intelligence hallucination and unfounded assertions. Similarly, any images generated through the platform include detailed methodology documentation explaining how the visualisation was constructed, enabling peer review and validation processes essential to scientific practice.
The competitive landscape has intensified as both Anthropic and rival OpenAI have dedicated substantial resources throughout the past year to developing professional-grade AI applications spanning financial services, healthcare, scientific research, and legal practice. Both companies explicitly target enterprise and institutional customers rather than consumer markets, viewing professional sector penetration as the pathway to justifying extraordinary venture valuations and establishing sustainable competitive moats. This strategic orientation explains Anthropic's emphasis on scientific credibility, compliance with regulatory frameworks, and partnerships with established pharmaceutical leaders—each component designed to build institutional confidence in AI-assisted research methodologies.
The emergence of Claude Science within Malaysian and broader Southeast Asian contexts carries important implications for the region's scientific and pharmaceutical development trajectories. As a developing-economy region with growing research capabilities and significant gaps in drug discovery infrastructure, Southeast Asia could potentially leverage such tools to accelerate research productivity and reduce the technological distance separating the region from leading global research institutions. However, the restricted access model—initially available only to paid Anthropic subscribers—introduces barriers that may limit adoption among academic institutions with constrained budgets, potentially widening technology access gaps between well-funded and resource-limited research environments.
Looking forward, the success of Claude Science will likely hinge on achieving what Amodei described as demonstrable success in identifying new drug discovery targets within the coming twelve-month period. This relatively short timeframe reflects the urgency both Anthropic and the pharmaceutical industry feel to transition from theoretical potential to concrete achievements. For Malaysian stakeholders—whether in academic research, pharmaceutical development, or technology policy—monitoring Claude Science's actual performance outcomes will be essential for informed decision-making about whether and how to integrate such tools into domestic research infrastructure.
